D. Boral Capital Cuts Invivyd (NASDAQ:IVVD) Price Target to $1.00

Invivyd (NASDAQ:IVVD) had its price objective cut by D. Boral Capital from $3.00 to $1.00 in a report released on Monday,Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Invivyd in a report on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $3.18.

Invivyd Trading Down 15.5%

Shares of IVVD opened at $0.87 on Monday. The company has a market cap of $104.52 million, a price-to-earnings ratio of -0.95 and a beta of 0.51. Invivyd has a 1-year low of $0.35 and a 1-year high of $2.74. The company’s fifty day simple moving average is $0.73 and its 200 day simple moving average is $0.80.

Invivyd (NASDAQ:IVVD) last issued its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. As a group, research analysts forecast that Invivyd will post -1.64 earnings per share for the current year.

Insider Transactions at Invivyd

In other news, insider Jill Andersen sold 49,402 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total transaction of $28,159.14. Following the completion of the sale, the insider owned 84,446 shares of the company’s stock, valued at $48,134.22. This trade represents a 36.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders have sold 277,654 shares of company stock worth $167,215. 25.40% of the stock is currently owned by company insiders.

Institutional Trading of Invivyd

Several large investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd bought a new stake in Invivyd during the 2nd quarter valued at $27,000. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares during the last quarter. Nuveen LLC bought a new stake in Invivyd in the 1st quarter valued at about $65,000. Invesco Ltd. raised its stake in Invivyd by 190.6% in the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after acquiring an additional 71,485 shares during the period. Finally, XTX Topco Ltd bought a new stake in Invivyd in the 1st quarter valued at about $66,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.